Skip to content

Welcome

Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

AAOA Member Benefits

  • Up to 60% discount for CME programs and free Annual Meeting. All AAOA’s CME programs meet ABOTOHNS Continuing Certification.
  • AAOA US ENT Affinity program, where AAOA members can gain savings on antigen, allergy supplies, and any of the other 5 service lines US ENT offers. For more email info@usentpartners.com.
  • Tools and resources to comply with US General Chapter 797 and practice management tools.
  • Advocacy support.
  • And much more! Learn More

ADVOCACY UPDATES

USP General Chapter Pharmaceutical Compounding – Sterile Preparations

Latest Updates  on USP <797> On September 23, 2019, the United States Pharmacopeia has announced that,…

Read more

What you need to comply with the pending USP General Chapter Pharmaceutical Compounding — Sterile Preparations

3 key compliance criteria The new USP General Chapter <797> Sterile Compounding went into effect…

Read more

2019 AAOA Advanced Course in Allergy & immunology Optional USP 797 Compliance Workshop

Cost: $125 for AAOA members and $300 for non-members* in addition to AAOA Advanced Course registration…

Read more

Upcoming Dates

04/01/24: Fellow Exam Application Deadline
Learn more

06/01/24: Research Grant Cycle
Learn more

06/25/24: Membership Application Deadline to be eligible for AAOA Member rate for the 2024 Basic Course

08/02/24: Scientific Abstract Submission Deadline
Learn more

12/01/24: Research Grant Cycle
Learn more

EDUCATION

AAOA Advanced Course

The recorded course content is available until April 30, 2024. This year’s Advanced Course featured Laryngology and Skull Base Surgery with Nausheen Jamal, MD and Garret Choby, MD as featured faculty.

RESIDENTS

For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More

IFAR

Available Now

aaoaf-ifar

IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2024 AAOA Advanced Course in Allergy & Immunology - Hybrid
On-Demand Content Access Deadline:
April 30, 2024
Learn More and Register

2024 AAOA Basic Course in Allergy & Immunology - Hybrid
July 25-27, 2024
The Diplomat, Hollywood, Florida
Learn More and Register

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas
Learn More 

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Next Availability - April 1, 2024

News and Updates

CRS with/without Nasal Polyps Podcast Series: From Immune Pathways to Clinical Practice

In the first episode of CRS with/without Nasal Polyps Podcast Series: From Immune Pathways to Clinical…

Read more

DosedDaily: A Free Resource For Residents

The AAOA has partnered with DosedDaily to offer a free resource for residents to support…

Read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

Allergy News

Food Guidelines

Changing Policy

Food allergies are a growing health concern with a significant increase in reported prevalence. Allergic reactions to food can produce life-threatening anaphylaxis. Peanut allergy in particular is a significant public health problem with no proven treatment nor a cure at the present time. Peanut allergy often remains a life-long problem for many individuals, as less than 25% of peanut allergic patients are expected to regain tolerance. Current recommendations for management include strict avoidance and a prescription for an auto-injectable form of epinephrine.

The increase in prevalence of peanut allergy occurred during a period of time when there was conflicting guidance regard- ing preventative measures for the development of peanut allergy. Prior to the year 2000, there were no guidelines regarding the timing for the introduction of peanut-containing products nor were there any purposeful strategies to delay the introduction of peanut-containing products to try to prevent the development of allergic disease. But in 2000, the American Academy of Pediatrics recommended that “solid foods should not be introduced into the diet of high-risk infants until 6 months of age…and peanuts…until 1 years of age.”

This recommendation was reversed in 2008. At that time, AAP recommended that “the introduction of solid foods not be delayed past 4-6 months of age”. However they did not make any updated recommendations regarding the introduction of peanut-containing products.

The Learning Early About Peanut allergy (LEAP) study demonstrated that peanut-containing products can be safely introduced to high-risk infants between the ages of 4 to 11 months and that there is a monumental potential for peanut allergy prevention. The National Institutes of Allergy and Infectious Diseases (NIAID) recently published an addendum guideline regarding the prevention of peanut allergy in the US based on the findings from the LEAP study. [Togias A et al. Addendum guidelines for the prevention of peanut allergy in the United States. J Allergy CliniImmunol.
2017 Jan;139(1):29-44.]

The NIAID-sponsored guidelines include the following three addendum recommendations:

Infants with severe eczema, egg allergy, or both should have introduction of age-appropriate peanut-containing food as early as 4 to 6 months of age to reduce the risk of peanut allergy. The Expert Panel recommended to strongly consider evaluation by in vitro specific IgE testing and/or skin prick testing, and if necessary an oral food challenge. Then based on these results, introduce peanut-containing foods.

Infants with mild-to-moderate eczema should have introduction of age-appropriate peanut-containing food around 6 months of age, in accordance with family preferences and cultural practices, to reduce the risk of peanut allergy. The Expert Panel recommended that infants in this cate- gory may have dietary peanut introduced at home without an in-office evaluation. The Expert Panel recognized that some caregivers and healthcare providers may desire an office supervised feeding and/or evaluation.

Infants without eczema or any food allergy may have age-appropriate peanut-containing food freely introduced in their diet, together with other solid foods, and in accordance with family preferences and cultural practices.
There is an algorithm in the addendum guidelines to aid in assessing the high-risk infants in recommendation one.
For these high-risk infants, it is recommended that they be evaluated and undergo skin testing by a specialist before the introduction of peanut-containing products.

The Expert Panel did recognize that for those high-risk infants who do not have access to a specialist that testing for peanut-specific immunoglobulin E (sIgE) may be the preferred initial approach in certain instances.

The recommendations regarding when to introduce pea- nut-containing products into the diet have changed. New research demonstrated that early introduction of peanut-
containing products around 4 to 6 months of age significantly reduced the risk of development of peanut allergy.

Heading

Call To Action or Advertisement

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Call To Action or Advertisement

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Back To Top